- Home
- DLHC vs ABOS Comparison
DLHC vs ABOS Comparison
Compare DLHC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- ABOS
- Stock Information
- Founded
- DLHC 1969
- ABOS 1996
- Country
- DLHC United States
- ABOS United States
- Employees
- DLHC N/A
- ABOS N/A
- Industry
- DLHC Business Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- ABOS Health Care
- Exchange
- DLHC Nasdaq
- ABOS Nasdaq
- Market Cap
- DLHC 79.6M
- ABOS 72.7M
- IPO Year
- DLHC N/A
- ABOS 2021
- Fundamental
- Price
- DLHC $5.64
- ABOS $1.16
- Analyst Decision
- DLHC
- ABOS Strong Buy
- Analyst Count
- DLHC 0
- ABOS 4
- Target Price
- DLHC N/A
- ABOS $6.50
- AVG Volume (30 Days)
- DLHC 106.0K
- ABOS 570.9K
- Earning Date
- DLHC 07-30-2025
- ABOS 08-12-2025
- Dividend Yield
- DLHC N/A
- ABOS N/A
- EPS Growth
- DLHC 75.08
- ABOS N/A
- EPS
- DLHC 0.38
- ABOS N/A
- Revenue
- DLHC $377,074,000.00
- ABOS N/A
- Revenue This Year
- DLHC N/A
- ABOS N/A
- Revenue Next Year
- DLHC N/A
- ABOS N/A
- P/E Ratio
- DLHC $15.76
- ABOS N/A
- Revenue Growth
- DLHC N/A
- ABOS N/A
- 52 Week Low
- DLHC $2.72
- ABOS $0.86
- 52 Week High
- DLHC $11.99
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- DLHC 56.89
- ABOS 51.76
- Support Level
- DLHC $5.66
- ABOS $1.12
- Resistance Level
- DLHC $5.97
- ABOS $1.26
- Average True Range (ATR)
- DLHC 0.21
- ABOS 0.08
- MACD
- DLHC -0.01
- ABOS -0.01
- Stochastic Oscillator
- DLHC 51.47
- ABOS 42.31
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.